ACST Stock – (NASDAQ: ACST) is actually providing an update on the use
As necessary pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or perhaps the “Company”) ACST Stock (NASDAQ: ACST – TSX-V: ACST) is giving an update on the usage of its “at-the market” equity offering plan.
As earlier disclosed, Acasti entered into an amended as well as restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and H.C. Wainwright & Co., LLC (collectively, the “Agents”), to implement a “at the market” equity offering program under which Acasti may issue as well as promote from time to time the everyday shares of its having an aggregate offering price of up to seventy five dolars million throughout the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the end distributions found on January 27, 2021, Acasti given an aggregate of 20,159,229 common shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 million. The ATM Shares ended up being offered at prevailing market costs averaging US$1.0747 per share. No securities had been sold throughout the facilities of the TSXV or, to the knowledge of the Company, in Canada. The ATM Shares were offered pursuant to a U.S. registration statement on Form S 3 (No. 333 239538) as made effective on July 7, 2020, and also the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate gross proceeds raised was paid to the Agents in connection with the services of theirs. As a consequence of the recent ATM sales, Acasti has a total of 200,119,659 typical shares issued and outstanding as of March five, 2021.
The extra capital raised has strengthened Acasti’s balance sheet and often will deliver the Company with supplemental freedom in its ongoing review process to enjoy and evaluate strategic alternatives.
About Acasti – ACST Stock
Acasti is a biopharmaceutical innovator that has historically concentrated on the research, development and commercialization of prescribed drugs using OM3 greasy acids delivered both as free fatty acids and bound-to-phospholipid esters, created from krill oil. OM3 fatty acids have extensive clinical evidence of safety as well as efficacy for lowering triglycerides in people with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being developed for people with severe HTG.
Forward Looking Statements – ACST Stock
Statements in this press release that are not statements of current or historical fact constitute “forward looking information” to the meaning of Canadian securities laws and “forward-looking statements” within the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward looking statements include known and unknown risks, uncertainties, along with other unknown variables that may result in the particular outcomes of Acasti to be materially different from historical results and as a result of any future outcomes expressed or perhaps implied by such forward-looking statements. In addition to statements which explicitly describe these types of risks as well as uncertainties, people are actually urged to look at statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or other related expressions to be forward-looking and uncertain. Readers are actually cautioned not to place undue reliance on these forward looking statements, which speak only as of the day of this particular press release. Forward-looking claims in this press release include, but are not confined to, statements or info concerning Acasti’s strategy, succeeding operations as well as the review of its of strategic alternatives.
The forward-looking statements found in this press release are expressly qualified in the entirety of theirs by this alerting statement, the “Special Note Regarding Forward-Looking Statements” area contained in Acasti’s latest annual report on Form 10-K and quarterly report on Form 10-Q, which are actually readily available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com as well as on the investor section of Acasti’s website at www.acastipharma.com. Most forward looking assertions in this press release exist as of the particular date of this press release.
ACST Stock – Acasti doesn’t undertake to upgrade any such forward looking statements whether as a direct result of information that is brand new , future events or otherwise, except as required by law. The forward-looking statements contained herein are also subject typically to assumptions and risks as well as uncertainties that are described from time to time in Acasti’s public securities filings with the Securities as well as exchange Commission and The Canadian securities commissions, like Acasti’s newest annual report on Form 10 K and quarterly report on Form 10-Q under the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is actually giving an update on the use